{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:41:47Z","timestamp":1782963707913,"version":"3.54.5"},"reference-count":42,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute, National Institutes of Health","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Multiple Endocrine Neoplasia type 2 (MEN2) is a genetic cancer syndrome for which there are limited data pertaining to the quality of life and psychosocial experiences of persons affected. Medullary thyroid carcinoma (MTC) is a rare disease of the thyroid gland often associated with MEN2. MTC often progresses slowly and may present with a myriad of physical symptoms including hair loss, sleep disturbance, fatigue, weight changes, heart palpitations, and constipation or diarrhea. Like other cancers or rare, inheritable illnesses, patients with MEN2 and MTC may be at risk for psychosocial stressors. The current, cross-sectional study administered a structured psychosocial interview and The Distress Thermometer\/Problem Checklist to 63 patients with MEN2 and MTC and their caregivers. Despite reports of overall good health, 46% of adults and 44% of youth reported that pain interferes with their daily life; 53% of adults and 59% of youth reported that pain interferes with their mood. Pediatric patients frequently reported experiencing attention challenges (50%) and difficulty concentrating (65%). Parents reported that mood shifts and becoming upset easily were the most prevalent concerns for their children. The most frequent need for services included education about MTC, treatment and research participation, and the opportunity to meet others with MTC.<\/jats:p>","DOI":"10.3390\/children9060774","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T08:41:33Z","timestamp":1653468093000},"page":"774","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC)"],"prefix":"10.3390","volume":"9","author":[{"given":"Robin","family":"Lockridge","sequence":"first","affiliation":[{"name":"Clinical Research Directorate (CRD), Frederick National Library for Cancer Research, Frederick, MD 21701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Bedoya","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Allen","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Widemann","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srivandana","family":"Akshintala","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glod","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9573-8870","authenticated-orcid":false,"given":"Lori","family":"Wiener","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3747\/co.26.5553","article-title":"A Primer on the Genetics of Medullary Thyroid Cancer","volume":"26","author":"Larouche","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","article-title":"Medullary thyroid carcinoma: Clinical characteris-tics, treatment, prognostic factors, and a comparison of staging systems","volume":"88","author":"Kebebew","year":"2000","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"150921","DOI":"10.1016\/j.sempedsurg.2020.150921","article-title":"Medullary Thyroid Carcinoma in Children","volume":"29","author":"Graves","year":"2020","journal-title":"Semin. Pediatr. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis","volume":"276","author":"Eng","year":"1996","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/thy.2005.15.531","article-title":"RETProto-Oncogene: A Review and Update of Genotype\u2013Phenotype Correlations in Hereditary Medullary Thyroid Cancer and Associated Endocrine Tumors","volume":"15","author":"Kouvaraki","year":"2005","journal-title":"Thyroid"},{"key":"ref_6","unstructured":"Adam, M.P., Ardinger, H.H., and Pagon, R.A. (1999). GeneReviews\u00ae, University of Washington."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40291-017-0289-5","article-title":"Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases","volume":"21","author":"Rajabi","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrendo.2011.139","article-title":"Management of medullary thyroid carcinoma and MEN2 syndromes in childhood","volume":"7","author":"Waguespack","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_10","first-page":"105","article-title":"Multiple endocrine neoplasia, type 2b","volume":"8","author":"Carney","year":"1978","journal-title":"Pathobiol. Annu."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.semcancer.2021.03.035","article-title":"Multiple endocrine neoplasia type 2: A review","volume":"79","author":"Mathiesen","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1530\/ERC-17-0209","article-title":"A comprehensive review on MEN2B","volume":"25","author":"Castinetti","year":"2018","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J. Clin. Endo-Crinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/oxfordjournals.annonc.a059049","article-title":"A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group","volume":"6","author":"Bajetta","year":"1995","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/thy.1995.5.407","article-title":"Medullary thyroid carcinoma: Recent advances and management update","volume":"5","author":"Marsh","year":"1995","journal-title":"Thyroid"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2265.1998.00392.x","article-title":"Prognostic factors for survival and for biochemical cure in medullary thyroid carcino-ma: Results in 899 patients. The GETC Study Group.Groupe d\u2019etude des tumeurs a calcitonine","volume":"48","author":"Modigliani","year":"1998","journal-title":"Clin. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1054\/bjoc.2000.1314","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d\u2019Etude des Tumeurs a Calcitonine (GETC)","volume":"83","author":"Nocera","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jso.20184","article-title":"Medullary thyroid carcinoma: Including MEN 2A and MEN 2B syndromes","volume":"89","author":"Quayle","year":"2005","journal-title":"J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K","article-title":"Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"73","author":"Wu","year":"1994","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3803\/EnM.2021.1082","article-title":"Current Guidelines for Management of Medullary Thyroid Carcinoma","volume":"36","author":"Kim","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-17-0325","article-title":"Advances in the management of MEN2: From improved surgical and medical treatment to novel kinase inhibitors","volume":"25","author":"Wells","year":"2018","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ando.2021.12.002","article-title":"Updates on therapy for medullary thyroid cancer in 2021","volume":"83","author":"Puerto","year":"2022","journal-title":"Ann. D\u2019endocrinologie"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10689-005-0656-y","article-title":"Multiple endocrine neoplasia type 2","volume":"4","author":"Peczkowska","year":"2005","journal-title":"Fam. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0029-1211946","article-title":"Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes","volume":"106","author":"Wells","year":"1998","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.lpm.2018.03.005","article-title":"Update on multiple endocrine neoplasia Type 1 and 2","volume":"47","author":"Baudry","year":"2018","journal-title":"Presse Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","article-title":"Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: An international, multicentre, retrospective study","volume":"7","author":"Castinetti","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1188\/06.CJON.571-575","article-title":"Medullary Thyroid Cancer and the Impact of Genetic Testing","volume":"10","author":"Keatts","year":"2006","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cen.14366","article-title":"Impact of gastrointestinal symptoms on quality of life in MEN2","volume":"94","author":"Goncharova","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1008349318728","article-title":"Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: A multicentric pilot-evaluation","volume":"10","author":"Freyer","year":"1999","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1023\/A:1012593410510","article-title":"Quality of life in patients at risk of medullary thyroid carcinoma and followed by a comprehensive medical network: Trends for future evalua-tions","volume":"12","author":"Freyer","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1089\/thy.2016.0148","article-title":"Assessment of Depression, Anxiety, Quality of Life, and Coping in Long-Standing Multiple Endocrine Neoplasia Type 2 Patients","volume":"27","author":"Rodrigues","year":"2017","journal-title":"Thyroid. Off. J. Am. Thyroid. Assoc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1210\/js.2018-00371","article-title":"Quality of Life and Coping in Multiple Endocrine Neoplasia Type 2","volume":"3","author":"Correa","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/ERC-17-0335","article-title":"Patient quality of life and prognosis in multiple endocrine neoplasia type 2","volume":"25","author":"Grey","year":"2018","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00520-012-1426-7","article-title":"Gastrointestinal stromal tumor: Psychosocial characteristics and con-siderations","volume":"20","author":"Wiener","year":"2012","journal-title":"Support Care Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/cncr.20940","article-title":"Screening for psychologic distress inambulatory cancer patients","volume":"103","author":"Jacobsen","year":"2005","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/pon.1320","article-title":"Screening cancer patients\u2019 families with the distress thermometer (DT): A validation study","volume":"17","author":"Zwahlen","year":"2008","journal-title":"Psycho-Oncology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/pon.993","article-title":"Validation of the Distress Thermometer with bone marrow transplant patients","volume":"15","author":"Ransom","year":"2006","journal-title":"Psycho-Oncology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/pon.1859","article-title":"Distress screening, rater agreement, and services in pediatric oncology","volume":"20","author":"Patel","year":"2011","journal-title":"Psycho-Oncology"},{"key":"ref_39","unstructured":"(2022, February 10). Available online: https:\/\/nces.ed.gov\/programs\/coe\/pdf\/2021\/cgg_508c.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1023252107120","article-title":"Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1)","volume":"2","author":"Berglund","year":"2003","journal-title":"Fam. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.surg.2018.04.036","article-title":"Quality of life in multiple endocrine neoplasia type 2A compared with normative and disease populations","volume":"164","author":"Mongelli","year":"2018","journal-title":"Surgery"},{"key":"ref_42","unstructured":"Hetherington, K., Hunter, J., Lockridge, R., Warby, M., Raygada, M., Wakefield, C., and Wiener, L. The psychosocial impacts of FECS on the patient and caregiver. In Familial Endocrine Cancer Syndromes: Navigating the Transition of Care for Pediatric and Adolescent Patients, in press."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/9\/6\/774\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:16Z","timestamp":1760138296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/9\/6\/774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["children9060774"],"URL":"https:\/\/doi.org\/10.3390\/children9060774","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}